SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

Natural "off switch" could slow or even reverse the growth of aggressive tumors.

The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different ...

Breakthrough discovery in cancer research! Scientists uncover a simple genetic strategy to combat aggressive cancers. Learn ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The Phase I/II trial sought to establish the impact of DYNE-251 on mobility-related endpoints, seeing an increase over ...

A study reveals how cancer disrupts RNA splicing and presents a potential therapy using antisense oligonucleotides to target ...

In a surprising turn of events, football player Exon has chosen to leave behind the traditional football scene to join a beach football league team after parting ways with Chengdu Rongcheng. This ...